The FDA approved Lerochol, a monthly PCSK9 inhibitor, for adults with hypercholesterolemia to reduce LDL-C levels alongside diet and exercise.

According to a study, Atherosclerotic Cardiovascular Disease (ASCVD) is the leading cause of heart attack and stroke, ...

There is increasing evidence that gum disease is associated with increased risk of cardiovascular events, including heart ...

There is increasing evidence that gum disease is associated with increased risk of cardiovascular events, including heart ...

Atom Therapeutics, a clinical stage biotechnology company developing best-in-class treatments for inflammatory and metabolic diseases, today announced FDA approval of a Phase II clinical trial ...

Investigators sought to evaluate changes in the estimated CV risk of men with prostate cancer after 6 months of hormone therapy using clinical tools established for the general population.

Current medical screening techniques could be failing to catch nearly half of those who experience a heart attack, according ...

Effective prevention and treatment of gum disease, also called periodontal disease, could potentially decrease the burden of cardiovascular disease, according to a new scientific statement published ...

Uterine fibroids are associated with an increased risk for atherosclerotic cardiovascular disease (ASCVD) up to 10 years after diagnosis.

AstraZeneca ($AZN) announced an update on their ongoing clinical study. Study Overview: AstraZeneca recently completed a Phase 1b study titled A ...

The larger risk reductions were not explained by changes in LDL cholesterol, suggesting something else is at play.

This increased risk held across all individual components of the composite ASCVD endpoint (coronary artery disease, ...